GlassScriptPhysician profile
Jenny Mink
NPI 1417425257
$5,912.28
in general payments reported to CMS, 2019-2025
52 companies · $1,907 in 2025
The $1,907 reported for 2025 was more than what 93% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $477 · 2022: $431 · 2023: $1,536 · 2024: $1,561 · 2025: $1,907.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,741 · Education: $263.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,741.27 |
| Education | $262.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $672.88 | 2021-2025 | Imfinzi, Enhertu, Tagrisso |
| Janssen Biotech, INC. | $609.45 | 2022-2025 | Imbruvica, Tecvayli, Darzalex |
| Regeneron Healthcare Solutions, INC. | $542.23 | 2021-2025 | Libtayo |
| Merck Sharp & Dohme LLC | $319.83 | 2023-2025 | Keytruda, Lynparza, Keytruda Qlex |
| Aveo Pharmaceuticals, INC. | $270.19 | 2021-2025 | |
| Novartis Pharmaceuticals Corporation | $266.70 | 2024-2025 | |
| Daiichi Sankyo INC. | $204.58 | 2022-2025 | Enhertu |
| Abbvie INC. | $194.83 | 2024-2025 | |
| Incyte Corporation | $194.66 | 2023-2025 | Monjuvi, Jakafi, Pemazyre |
| Genzyme Corporation | $193.75 | 2023-2025 | |
| Sobi, INC | $175.82 | 2023-2025 | |
| Eisai INC. | $149.88 | 2022-2025 | |
| Jazz Pharmaceuticals INC. | $133.92 | 2023-2025 | |
| Kite Pharma, INC. | $116.34 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $107.46 | 2022-2025 |
Show all 52 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $103.17 | 2022-2025 | Reblozyl, Pomalyst |
| Blueprint Medicines Corporation | $102.20 | 2021 | |
| Exelixis INC. | $99.60 | 2023-2025 | Cabometyx |
| Genentech USA, INC. | $94.86 | 2023-2025 | Tecentriq, Venclexta |
| Pfizer INC. | $94.31 | 2024-2025 | |
| Servier Pharmaceuticals LLC | $93.63 | 2023-2025 | |
| Gilead Sciences, INC. | $89.00 | 2023 | Trodelvy |
| E.R. Squibb & Sons, L.L.C. | $79.46 | 2022-2025 | Opdualag |
| Pharmaessentia USA Corporation | $70.24 | 2024 | Besremi |
| Alexion Pharmaceuticals, INC. | $61.81 | 2023-2025 | Ultomiris |
| Tersera Therapeutics LLC | $58.44 | 2023-2024 | Xermelo |
| Beigene USA, INC. | $56.53 | 2023-2024 | Brukinsa, Tevimbra |
| Genmab U.S., INC. | $53.72 | 2024-2025 | Epkinly |
| Takeda Pharmaceuticals U.S.A., INC. | $53.62 | 2024 | Alunbrig, Ninlaro |
| Glaxosmithkline, LLC. | $50.51 | 2024-2025 | Ojjaara |
| Puma Biotechnology, INC. | $50.03 | 2022-2024 | |
| Seagen INC. | $47.66 | 2023 | Tukysa, Tivdak |
| G1 Therapeutics, INC. | $43.88 | 2022-2023 | Cosela |
| Stemline Therapeutics INC. | $40.57 | 2024-2025 | Orserdu |
| Sumitomo Pharma America, INC. | $36.50 | 2025 | Orgovyx |
| Karyopharm Therapeutics INC. | $34.99 | 2024 | Xpovio |
| Astellas Pharma US INC | $30.66 | 2025 | Xtandi |
| Rigel Pharmaceuticals, INC. | $30.21 | 2022-2023 | Tavalisse, Rezlidhia |
| Beone Medicines USA, INC. | $27.40 | 2025 | Tevimbra |
| Deciphera Pharmaceuticals INC. | $25.66 | 2025 | Qinlock, Romvimza |
| Array Biopharma INC | $24.12 | 2025 | Lorbrena, Bosulif, Braftovi |
| Corcept Therapeutics | $21.82 | 2025 | Korlym |
| Dendreon Pharmaceuticals LLC | $21.63 | 2024 | Provenge |
| Taiho Oncology, INC. | $21.54 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $20.76 | 2023 | Imbruvica |
| Mirati Therapeutics, INC. | $19.88 | 2024 | Krazati |
| Emd Serono, INC. | $19.51 | 2024 | |
| Lilly USA, LLC | $18.51 | 2024 | Verzenio |
| Morphosys, US INC. | $18.00 | 2023 | Monjuvi |
| Coherus Oncology, INC. | $16.73 | 2024 | |
| Cycle Pharmaceuticals INC | $15.36 | 2025 | Phyrago |
| Amgen INC. | $13.24 | 2023 | Vectibix, Xgeva, Nplate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jenny Mink listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.